Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

A Targeted, Differential Top-Down Proteomic Methodology for Comparison of ApoA-I Proteoforms in Individuals with High and Low HDL Efflux Capacity.

Seckler HDS, Fornelli L, Mutharasan RK, Thaxton CS, Fellers R, Daviglus M, Sniderman A, Rader D, Kelleher NL, Lloyd-Jones DM, Compton PD, Wilkins JT.

J Proteome Res. 2018 Jun 1;17(6):2156-2164. doi: 10.1021/acs.jproteome.8b00100. Epub 2018 Apr 27.

PMID:
29649363
2.

Small interfering RNAs based on huntingtin trinucleotide repeats are highly toxic to cancer cells.

Murmann AE, Gao QQ, Putzbach WE, Patel M, Bartom ET, Law CY, Bridgeman B, Chen S, McMahon KM, Thaxton CS, Peter ME.

EMBO Rep. 2018 Mar;19(3). pii: e45336. doi: 10.15252/embr.201745336. Epub 2018 Feb 12.

PMID:
29440125
3.

Nitric Oxide-Delivering High-Density Lipoprotein-like Nanoparticles as a Biomimetic Nanotherapy for Vascular Diseases.

Rink JS, Sun W, Misener S, Wang JJ, Zhang ZJ, Kibbe MR, Dravid VP, Venkatraman S, Thaxton CS.

ACS Appl Mater Interfaces. 2018 Feb 28;10(8):6904-6916. doi: 10.1021/acsami.7b18525. Epub 2018 Feb 13.

PMID:
29385802
4.

HDL nanoparticles targeting sonic hedgehog subtype medulloblastoma.

Bell JB, Rink JS, Eckerdt F, Clymer J, Goldman S, Thaxton CS, Platanias LC.

Sci Rep. 2018 Jan 19;8(1):1211. doi: 10.1038/s41598-017-18100-8.

5.

Scavenger Receptor Type B1 and Lipoprotein Nanoparticle Inhibit Myeloid-Derived Suppressor Cells.

Plebanek MP, Bhaumik D, Bryce PJ, Thaxton CS.

Mol Cancer Ther. 2018 Mar;17(3):686-697. doi: 10.1158/1535-7163.MCT-17-0981. Epub 2017 Dec 27.

PMID:
29282300
6.

Induction of DISE in ovarian cancer cells in vivo.

Murmann AE, McMahon KM, Haluck-Kangas A, Ravindran N, Patel M, Law CY, Brockway S, Wei JJ, Thaxton CS, Peter ME.

Oncotarget. 2017 Oct 4;8(49):84643-84658. doi: 10.18632/oncotarget.21471. eCollection 2017 Oct 17.

7.

Pre-metastatic cancer exosomes induce immune surveillance by patrolling monocytes at the metastatic niche.

Plebanek MP, Angeloni NL, Vinokour E, Li J, Henkin A, Martinez-Marin D, Filleur S, Bhowmick R, Henkin J, Miller SD, Ifergan I, Lee Y, Osman I, Thaxton CS, Volpert OV.

Nat Commun. 2017 Nov 6;8(1):1319. doi: 10.1038/s41467-017-01433-3.

8.

Rational Targeting of Cellular Cholesterol in Diffuse Large B-Cell Lymphoma (DLBCL) Enabled by Functional Lipoprotein Nanoparticles: A Therapeutic Strategy Dependent on Cell of Origin.

Rink JS, Yang S, Cen O, Taxter T, McMahon KM, Misener S, Behdad A, Longnecker R, Gordon LI, Thaxton CS.

Mol Pharm. 2017 Nov 6;14(11):4042-4051. doi: 10.1021/acs.molpharmaceut.7b00710. Epub 2017 Oct 3.

PMID:
28933554
9.

Engineered nanoparticles for the detection, treatment and prevention of atherosclerosis: how close are we?

Nguyen LTH, Muktabar A, Tang J, Dravid VP, Thaxton CS, Venkatraman S, Ng KW.

Drug Discov Today. 2017 Sep;22(9):1438-1446. doi: 10.1016/j.drudis.2017.07.006. Epub 2017 Jul 18. Review.

PMID:
28733245
10.

Properties of Native High-Density Lipoproteins Inspire Synthesis of Actively Targeted In Vivo siRNA Delivery Vehicles.

McMahon KM, Plebanek MP, Thaxton CS.

Adv Funct Mater. 2016 Nov 15;26(43):7824-7835. doi: 10.1002/adfm.201602600. Epub 2016 Sep 20.

11.

Systemically administered collagen-targeted gold nanoparticles bind to arterial injury following vascular interventions.

Meyers MW, Rink JS, Jiang Q, Kelly ME, Vercammen JM, Thaxton CS, Kibbe MR.

Physiol Rep. 2017 Feb;5(4). pii: e13128. doi: 10.14814/phy2.13128. Epub 2017 Feb 27.

12.

Synthetic high-density lipoproteins as targeted monotherapy for chronic lymphocytic leukemia.

McMahon KM, Scielzo C, Angeloni NL, Deiss-Yehiely E, Scarfo L, Ranghetti P, Ma S, Kaplan J, Barbaglio F, Gordon LI, Giles FJ, Thaxton CS, Ghia P.

Oncotarget. 2017 Feb 14;8(7):11219-11227. doi: 10.18632/oncotarget.14494.

13.

HDL efflux capacity, HDL particle size, and high-risk carotid atherosclerosis in a cohort of asymptomatic older adults: the Chicago Healthy Aging Study.

Mutharasan RK, Thaxton CS, Berry J, Daviglus ML, Yuan C, Sun J, Ayers C, Lloyd-Jones DM, Wilkins JT.

J Lipid Res. 2017 Mar;58(3):600-606. doi: 10.1194/jlr.P069039. Epub 2017 Jan 3.

14.

Molecular Dynamics Simulation and Experimental Studies of Gold Nanoparticle Templated HDL-like Nanoparticles for Cholesterol Metabolism Therapeutics.

Lai CT, Sun W, Palekar RU, Thaxton CS, Schatz GC.

ACS Appl Mater Interfaces. 2017 Jan 18;9(2):1247-1254. doi: 10.1021/acsami.6b12249. Epub 2017 Jan 5.

PMID:
28001031
15.

Lipoproteins and lipoprotein mimetics for imaging and drug delivery.

Thaxton CS, Rink JS, Naha PC, Cormode DP.

Adv Drug Deliv Rev. 2016 Nov 15;106(Pt A):116-131. doi: 10.1016/j.addr.2016.04.020. Epub 2016 Apr 29. Review.

16.

Circulating microRNA signature for the diagnosis of very high-risk prostate cancer.

Alhasan AH, Scott AW, Wu JJ, Feng G, Meeks JJ, Thaxton CS, Mirkin CA.

Proc Natl Acad Sci U S A. 2016 Sep 20;113(38):10655-60. doi: 10.1073/pnas.1611596113. Epub 2016 Sep 6.

17.
18.

Mosaic Interdigitated Structure in Nanoparticle-Templated Phospholipid Bilayer Supports Partial Lipidation of Apolipoprotein A-I.

Sun W, Wu W, McMahon KM, Rink JS, Thaxton CS.

Part Part Syst Charact. 2016 Jun;33(6):300-305. doi: 10.1002/ppsc.201600032. Epub 2016 Apr 8.

19.

High-Density Lipoproteins for Therapeutic Delivery Systems.

Mutharasan RK, Foit L, Thaxton CS.

J Mater Chem B. 2016 Jan 14;4(2):188-197. Epub 2015 Nov 24.

20.

Pathways for Modulating Exosome Lipids Identified By High-Density Lipoprotein-Like Nanoparticle Binding to Scavenger Receptor Type B-1.

Angeloni NL, McMahon KM, Swaminathan S, Plebanek MP, Osman I, Volpert OV, Thaxton CS.

Sci Rep. 2016 Mar 11;6:22915. doi: 10.1038/srep22915.

21.

Nanoparticle Targeting and Cholesterol Flux Through Scavenger Receptor Type B-1 Inhibits Cellular Exosome Uptake.

Plebanek MP, Mutharasan RK, Volpert O, Matov A, Gatlin JC, Thaxton CS.

Sci Rep. 2015 Oct 29;5:15724. doi: 10.1038/srep15724.

22.

Synthetic high-density lipoprotein-like nanoparticles as cancer therapy.

McMahon KM, Foit L, Angeloni NL, Giles FJ, Gordon LI, Thaxton CS.

Cancer Treat Res. 2015;166:129-50. doi: 10.1007/978-3-319-16555-4_6. Review.

23.

Mesophase in a thiolate-containing diacyl phospholipid self-assembled monolayer.

Sun W, Kewalramani S, Hujsak K, Zhang H, Bedzyk MJ, Dravid VP, Thaxton CS.

Langmuir. 2015 Mar 17;31(10):3232-41. doi: 10.1021/la504822q. Epub 2015 Mar 4.

PMID:
25695627
24.

Robust passive and active efflux of cellular cholesterol to a designer functional mimic of high density lipoprotein.

Luthi AJ, Lyssenko NN, Quach D, McMahon KM, Millar JS, Vickers KC, Rader DJ, Phillips MC, Mirkin CA, Thaxton CS.

J Lipid Res. 2015 May;56(5):972-85. doi: 10.1194/jlr.M054635. Epub 2015 Feb 4.

25.

Synthetic high-density lipoprotein-like nanoparticles for cancer therapy.

Foit L, Giles FJ, Gordon LI, Thaxton CS.

Expert Rev Anticancer Ther. 2015 Jan;15(1):27-34. doi: 10.1586/14737140.2015.990889. Epub 2014 Dec 9. Review.

26.

NanoFlares for the detection, isolation, and culture of live tumor cells from human blood.

Halo TL, McMahon KM, Angeloni NL, Xu Y, Wang W, Chinen AB, Malin D, Strekalova E, Cryns VL, Cheng C, Mirkin CA, Thaxton CS.

Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):17104-9. doi: 10.1073/pnas.1418637111. Epub 2014 Nov 17.

27.

High Density Lipoprotein Nanoparticles Deliver RNAi to Endothelial Cells to Inhibit Angiogenesis.

Tripathy S, Vinokour E, McMahon KM, Volpert OV, Thaxton CS.

Part Part Syst Charact. 2014 Nov 1;31(11):1141-1150.

28.

High-density lipoproteins for the systemic delivery of short interfering RNA.

McMahon KM, Thaxton CS.

Expert Opin Drug Deliv. 2014 Feb;11(2):231-47. doi: 10.1517/17425247.2014.866089. Epub 2013 Dec 9. Review.

29.

Knockdown of intraislet IKK╬▓ by spherical nucleic acid conjugates prevents cytokine-induced injury and enhances graft survival.

Rink JS, McMahon KM, Zhang X, Chen X, Mirkin CA, Thaxton CS, Kaufman DB.

Transplantation. 2013 Nov 27;96(10):877-84. doi: 10.1097/TP.0b013e3182a4190e.

30.

Update on current and potential nanoparticle cancer therapies.

Rink JS, Plebanek MP, Tripathy S, Thaxton CS.

Curr Opin Oncol. 2013 Nov;25(6):646-51. doi: 10.1097/CCO.0000000000000012. Review.

31.

Biomimetic, synthetic HDL nanostructures for lymphoma.

Yang S, Damiano MG, Zhang H, Tripathy S, Luthi AJ, Rink JS, Ugolkov AV, Singh AT, Dave SS, Gordon LI, Thaxton CS.

Proc Natl Acad Sci U S A. 2013 Feb 12;110(7):2511-6. doi: 10.1073/pnas.1213657110. Epub 2013 Jan 23.

32.

Templated high density lipoprotein nanoparticles as potential therapies and for molecular delivery.

Damiano MG, Mutharasan RK, Tripathy S, McMahon KM, Thaxton CS.

Adv Drug Deliv Rev. 2013 May;65(5):649-62. doi: 10.1016/j.addr.2012.07.013. Epub 2012 Aug 17. Review.

PMID:
22921597
33.

A novel mouse model that develops spontaneous arthritis and is predisposed towards atherosclerosis.

Rose S, Eren M, Murphy S, Zhang H, Thaxton CS, Chowaniec J, Waters EA, Meade TJ, Vaughan DE, Perlman H.

Ann Rheum Dis. 2013 Jan;72(1):89-95. doi: 10.1136/annrheumdis-2012-201431. Epub 2012 Jun 26.

34.

Scanometric microRNA array profiling of prostate cancer markers using spherical nucleic acid-gold nanoparticle conjugates.

Alhasan AH, Kim DY, Daniel WL, Watson E, Meeks JJ, Thaxton CS, Mirkin CA.

Anal Chem. 2012 May 1;84(9):4153-60. doi: 10.1021/ac3004055. Epub 2012 Apr 10.

35.

Tailoring of biomimetic high-density lipoprotein nanostructures changes cholesterol binding and efflux.

Luthi AJ, Zhang H, Kim D, Giljohann DA, Mirkin CA, Thaxton CS.

ACS Nano. 2012 Jan 24;6(1):276-85. doi: 10.1021/nn2035457. Epub 2011 Dec 1.

36.

Hybridization-induced "off-on" 19F-NMR signal probe release from DNA-functionalized gold nanoparticles.

Kieger A, Wiester MJ, Procissi D, Parrish TB, Mirkin CA, Thaxton CS.

Small. 2011 Jul 18;7(14):1977-81. doi: 10.1002/smll.201100566. Epub 2011 Jun 10. No abstract available.

PMID:
21661107
37.

Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study.

Eifler AC, Thaxton CS.

Methods Mol Biol. 2011;726:325-38. doi: 10.1007/978-1-61779-052-2_21.

PMID:
21424459
38.

Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery.

McMahon KM, Mutharasan RK, Tripathy S, Veliceasa D, Bobeica M, Shumaker DK, Luthi AJ, Helfand BT, Ardehali H, Mirkin CA, Volpert O, Thaxton CS.

Nano Lett. 2011 Mar 9;11(3):1208-14. doi: 10.1021/nl1041947. Epub 2011 Feb 14.

39.

Nanotechnology for synthetic high-density lipoproteins.

Luthi AJ, Patel PC, Ko CH, Mutharasan RK, Mirkin CA, Thaxton CS.

Trends Mol Med. 2010 Dec;16(12):553-60. doi: 10.1016/j.molmed.2010.10.006. Epub 2010 Nov 17.

40.

Transfection of pancreatic islets using polyvalent DNA-functionalized gold nanoparticles.

Rink JS, McMahon KM, Chen X, Mirkin CA, Thaxton CS, Kaufman DB.

Surgery. 2010 Aug;148(2):335-45. doi: 10.1016/j.surg.2010.05.013.

41.

Lymphotropic nanoparticle enhanced MRI for the staging of genitourinary tumors.

Mouli SK, Zhao LC, Omary RA, Thaxton CS.

Nat Rev Urol. 2010 Feb;7(2):84-93. doi: 10.1038/nrurol.2009.254. Epub 2010 Jan 19. Review.

PMID:
20084078
42.

Treatment outcomes of radical prostatectomy in potential candidates for 3 published active surveillance protocols.

Thaxton CS, Loeb S, Roehl KA, Kan D, Catalona WJ.

Urology. 2010 Feb;75(2):414-8. doi: 10.1016/j.urology.2009.07.1353. Epub 2009 Dec 5.

43.

Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy.

Thaxton CS, Elghanian R, Thomas AD, Stoeva SI, Lee JS, Smith ND, Schaeffer AJ, Klocker H, Horninger W, Bartsch G, Mirkin CA.

Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18437-42. doi: 10.1073/pnas.0904719106. Epub 2009 Oct 19.

44.

Templated spherical high density lipoprotein nanoparticles.

Thaxton CS, Daniel WL, Giljohann DA, Thomas AD, Mirkin CA.

J Am Chem Soc. 2009 Feb 4;131(4):1384-5. doi: 10.1021/ja808856z.

45.

A two-color-change, nanoparticle-based method for DNA detection.

Cao YC, Jin R, Thaxton CS, Mirkin CA.

Talanta. 2005 Sep 15;67(3):449-55. doi: 10.1016/j.talanta.2005.06.063. Epub 2005 Aug 10.

PMID:
18970188
46.

Combined prostate-specific antigen density and biopsy features to predict "clinically insignificant" prostate cancer.

Loeb S, Roehl KA, Thaxton CS, Catalona WJ.

Urology. 2008 Jul;72(1):143-7. doi: 10.1016/j.urology.2007.11.009. Epub 2008 Apr 24.

PMID:
18436287
47.

Retrieval of migrated ureteral stents by coaxial cannulation with a flexible ureteroscope and paired helical basket.

Meeks JJ, Helfand BT, Thaxton CS, Nadler RB.

J Endourol. 2008 May;22(5):927-9. doi: 10.1089/end.2007.0272.

PMID:
18429684
48.

Tumor characteristics of carriers and noncarriers of the deCODE 8q24 prostate cancer susceptibility alleles.

Helfand BT, Loeb S, Cashy J, Meeks JJ, Thaxton CS, Han M, Catalona WJ.

J Urol. 2008 Jun;179(6):2197-201; discussion 2202. doi: 10.1016/j.juro.2008.01.110. Epub 2008 Apr 18.

PMID:
18423739
49.

Radiographic parameters on noncontrast computerized tomography predictive of shock wave lithotripsy success.

Kacker R, Zhao L, Macejko A, Thaxton CS, Stern J, Liu JJ, Nadler RB.

J Urol. 2008 May;179(5):1866-71. doi: 10.1016/j.juro.2008.01.038. Epub 2008 Mar 18.

PMID:
18353389
50.

Comparison of prostate specific antigen velocity in screened versus referred patients with prostate cancer.

Meeks JJ, Thaxton CS, Loeb S, Roehl KA, Helfand BT, Catalona WJ.

J Urol. 2008 Apr;179(4):1340-3. doi: 10.1016/j.juro.2007.11.068. Epub 2008 Mar 4.

PMID:
18289590

Supplemental Content

Loading ...
Support Center